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Abstract: Lack of standardization of clinically compliant culture protocols of mesenchymal stem
cells for re-implantation in humans have hindered clinical progress in the field of tissue regeneration
to repair maxillofacial and orthopedic defects. The goal of this study was to establish a clinically
relevant osteogenic protocol for collection and expansion of autologous stem cells to be used at
Marshall University for re-implantation and repair of maxillofacial and orthopedic conditions.
Human bone marrow (hBM) samples were collected from patients undergoing intramedullary
nail fixation for closed femoral fractures. hBM mesenchymal cells were expanded by growing
them first in Petri dishes for two weeks, followed by a week of culture using Perfecta 3D Hanging
Drop Plates® . Various scaffold materials were tested and analyzed for cellular integration, vitality,
and differentiation capacity of harvested hBM-MSCs including: 60/40 blend of hydroxyapatite
biomatrix; Acellular bone composite discs; Allowash® , cancellous bone cubes; PLGA (poly
lactic-co-glycolic acid); and Woven chitin derived fiber. We found that the 3D spheroid culture
allowed production of hBM mesenchymal cells that retained osteoblast differentiation capacity over
a monolayer culture of hBM-MSCs without the need to use chemical or hormonal modulation.
We also observed that hydroxyapatite and Allowash cancellous bone scaffolds allowed better cell
integration and viability properties as compared to other materials tested in this study. In conclusion,
the multimodal culture methodology we developed creates actively differentiating stem-cell spheroids
that can then be readily utilized in clinical practices to improve the regeneration of tissues of the head
and the body.
Keywords: bone marrow mesenchymal stem cells; autologous transplant; regenerative medicine;
fracture healing; bone defects; traumatic injuries
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1. Introduction
The field of regenerative medicine is rapidly evolving and although stem cell technologies have
been exhaustively researched in the laboratory setting, they have not yet been widely integrated
into the clinical setting. This is largely due to a general lack of traditional clinical utility and
standardization that is necessary to implement these complex therapies in both a regulatory compliant
and consistent manner. One of the most widely studied stem cell applications is that of using adult
multipotent mesenchymal stem cells to assist in a variety of wound healing practices [1]. We present
a novel, clinically relevant osteogenic protocol for autologous mesenchymal stem cell expansion
and re-implantation.
Mesenchymal stem cells (MSCs) are renowned for their differentiation potential and versatility
in regenerative medicine for the treatment of a breadth of issues ranging from chronic diseases
to traumatic injury [2]. Bone marrow-derived MSCs (hBM-MSCs) are useful in healing traumatic
bone injuries by inducing osteo-regeneration. 5–10% of bone fractures result in a “non-union”
clinical outcome wherein the patient’s bone fails to heal itself from injury [3]-by introducing actively
differentiating MSC’s and thus reversing the process. More promising, such a developed technique
could be adapted to large osseous defects (even coupled to scaffolding techniques) and provide
an advanced means for autologous bone regeneration resulting from trauma, infections, and even
tumor resections. MSC therapies are not limited only to non-union fractures and could be used in
treating a variety of other traumatic or degenerative orthopaedic or maxillofacial illnesses such as
bone defects and cartilage replacement [2]. Use of MSCs has been focused most heavily on soft tissue
injury and immune disorders, but their utility has been implicated for the treatment of a variety of
other conditions.
In order to develop a clinical practice using MSCs, expansion of MSC populations in vitro is
critical to achieving a therapeutically relevant number of active cells [4]. In cases where the body
cannot heal itself via natural stem cell recruiting pathways the cause is often a defect in stem cell
induction and signaling pathways. In older individuals this may occur due to decreased overall
nutritional and growth factor deficits in the native stem cell environments. This natural aging process
has a direct impact on bone regenerative potential and MSCs decrease in both number and activity in
the body [5].
Cell-based therapies also often require the use of a biomatrix, also referred to as scaffold, to hold
the implanted cells in the intended local environment within the body at the site of injury [6]. In this
study widely available and FDA approved materials, including 60%/40% (matrix to pore space ratio)
hydroxyapatite blends, cancellous bone cubes, patient bone fragments prepared in an acellular manner,
PLGA poly(lactic-co-glycolic acid) constructs, and woven chitin bio fibers were assessed for their
compatibility with the expanded MSC populations.
MSC auto-transplantation protocols could be used to dramatically improve the outcomes of
serious bony defects and non-unions. However, the limiting factor of any such treatment option is
the time needed to expand an individual’s extracted stem-cell population [7]. Human bone marrow
mesenchymal stem cells (hBM-MSCs) can be cultured using a variety of different techniques and
methodologies, including traditional monolayer culture, biomatrix embedding of cells, and as of
recently, self-assembled spheroid culture [8]. Spheroid culture in vitro has been shown to exhibit
significant advantages over other traditional culture modalities regarding osteogenic potential,
cell-to-cell contact, up-regulation of osteogenic genes and proteins, and calcium auto-deposition
without the utilization of exogenous osteoblast inducer reagents (OIR) [9].
The protocol we developed cultures MSCs in vitro within a 3-week window. We combined two
methodologies: A traditional, two-dimensional substrate-based adherent monolayer method and a
three-dimensional spheroid culture method.
It is known that the ability of stem cells to form clonal colonies while maintaining multipotent
differentiation potential declines over successive expansions in a two-dimensional environment [10].
This is largely due to the polar nature of the monolayer itself. The layer of cells forms on the bottom
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of the plate and expands along a single plane. The polar, flat, nature of the cell population causes a
differential in media and nutrient exposure, thus increasing the possibility for heterogeneity within
the population of cells [11]. Another contributing drawback to monolayer culture is that cell-to-cell
surface contact is minimalized and therefore it keeps the cell population from being representative
of the in vivo behavior of MSCs in the body. This lack of cell signaling presents the need for
exogenous growth and differentiation factors in maintaining biologically active MSC populations
in vitro, further removing the population from an accurate representation of MSCs within the body.
To better simulate in-vivo conditions, three-dimensional (3-D) cell culture platforms have become
a major focus in regenerative medicine in recent years. Culturing stem-cells in a 3-D environment
where cell-cell contact is maximized has been shown to drastically improve the retention of “stemness”
qualities in MSCs [12]. This retained differentiation potential is vital in developing any effective stem
cell-based therapy, as re-implanting cells that have lost their functional ability to heal wounds would
be a futile endeavor.
2. Results
2.1. Human Bone Marrow (hBM) Sample Collection
Human bone marrow samples were obtained from four patients undergoing intramedullary nail
fixation for closed femoral fractures. Patients were selected based on their injuries and were enrolled
in an IRB protocol at Marshall University.
hBM samples were collected using either the reamer irrigator aspirator (RIA) and filtration
system for BM sample collection or the standard reaming techniques used to prepare the canal for
intramedullary implants. Waste blood and serum were collected with a bulb syringe or regular syringe
through the nailing portal immediately after reaming. Using these two techniques, mesenchymal
stem cells found in both the aspirated material and the collected bony fragments from the reaming
were collected.
We found that the RIA method of reaming is less optimal for the collection of viable stem cells.
In fact, better proliferative characteristics were observed from the “non-washed” standard reaming
collection even though the amount of material collected by this method is often limited.
2.2. MSC Characterization
Flow Cytometry analysis was used to characterize the primary cell populations derived from
patient donors in this study. Cell markers examined in this study were targeted to the mesenchymal
lineage of the native stem cell population present in adult human bone marrow. Table 1 displays
the markers that were assessed. The isolated cells were adherent to plastic and displayed fibroblast
morphology and surface markers, such as cluster of differentiation 44, 29, 105 and 73 (CD44, CD29,
CD105, and CD73), similarly to preparations of MSCs described by other groups derived from bone
marrow (BM) [13,14].
Table 1. Percentage of cell markers expression in cultured hBM-MSC.
Marker

CD-44

CD-29

CD-105

CD-73

BM001
BM002
BM004

97.10%
100%
95%

97.80%
100%
93.50%

97.00%
89.30%
96.80%

96.00%
94.00%
93.50%

The patient derived cell populations were also imaged on a regular basis to document their
growth rate and monitor for unexpected morphological changes. We found that the average in-vitro
doubling time of BM001 was 36 h, of BM002 was 120 h, and of BM004 was 23 h. Figure 1 (a and b)
show images taken at weeks 1 and 3 of the hBM-MSCs bi-dimensional expansion, respectively [15].
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2.3. Patient Derived Serum Supplementation Efficacy

Cell number

2.3.of
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the novel
and
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aspects ofEfficacy
our stem cell expansion protocol is the use of patient
derived growth
factors
in
place
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protocolfactors.
is the use
patient
all-mainstream
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culture
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bovine
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are
added
to
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basal
culture
derived growth factors in place of the industry standard animal derived growth factors. For virtually
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in order to facilitate
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This
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based
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fetal[15].
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with
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in order
to facilitate
cell FDA
proliferation
[15]. The
Thisdescribed
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described
protocol
a supply
of growth
factors effective,
that are directly
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the patient
whose cellsThe
are being
expanded
for
substitutes
FBS
with
a
supply
of
growth
factors
that
are
directly
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from
the
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whose
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therapeutic purposes. This serum, herein referred to as patient derived serum (PDS), was found to not
being
expanded
forwas
therapeutic
purposes.
This serum,
herein referred
to as expansion
patient derived
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only beare
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substitute,
but
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effective
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the in-vitro
of primary
(PDS),
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to
not
only
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a
fit
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but
was
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more
effective
at
promoting
the
inmesenchymal cell populations under the conditions used in this protocol. The patient derived stem
vitro expansion of primary mesenchymal cell populations under the conditions used in this protocol.
cell populations were cultured using media formulations employing either FBS or PDS and assessed
The patient derived stem cell populations were cultured using media formulations employing either
for colony population at regular 24-h intervals for 5 consecutive days. The results are displayed in
FBS or PDS and assessed for colony population at regular 24-h intervals for 5 consecutive days. The
Figure 2 and Table 2. We observed that the hBM-MSC cultured using the patient own derived serum
results are displayed in Figure 2 and Table 2. We observed that the hBM-MSC cultured using the
grew faster
in three different replica experiments (8.4; 7.7; and 8.7 fold increase) than those cultured
patient own derived serum grew faster in three different replica experiments (8.4; 7.7; and 8.7 fold
with fetal
bovine
serum
(5.8;
7.1; and
5.9fetal
foldbovine
increase)
with
a 7.1;
calculated
8.3 cumulative
average
increase)
than
those
cultured
with
serum
(5.8;
and 5.9 6.3
foldvs.
increase)
with a calculated
fold increase,
respectively
(p
≤
0.05).
6.3 vs. 8.3 cumulative average fold increase, respectively (p ≤ 0.05).

Hours
Figure 2.Figure
Comparison
of hBM-MSCs
growthgrowth
using media
with patient-derived
serum
2. Comparison
of hBM-MSCs
using supplemented
media supplemented
with patient-derived
serum
vs.serum
fetal bovine
(FBS). The
diagram represents
grow
curves
(cell number
overof
(PDS) vs.
fetal(PDS)
bovine
(FBS).serum
The diagram
represents
grow curves
(cell
number
over time)
time)
of hBM-MSC
BM002,
and BM004)
grown using
medium supplemented
with FBSto
hBM-MSC
(BM001,
BM002,(BM001,
and BM004)
grown
using medium
supplemented
with FBS Compared
Compared
to PDS over 72 h.
PDS over
72 h.
Table 2. number of cells and comparative folds increase of cell growth over 72 h.

Hours
24

FBS
BM001
500 cells

PDS
BM001
500 cells

FBS
BM002
500 cells

PDS
BM002
500 cells

FBS
BM004
500 cells

PDS
BM004
500 cells
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Table 2. Number of cells and comparative folds increase of cell growth over 72 h.
FBS
BM001

PDS
BM001

FBS
BM002

PDS
BM002

FBS
BM004

PDS
BM004

500 cells
746 cells
933 cells
1480 cells
2900 cells

500 cells
720 cells
1300 cells
1753 cells
4240 cells

500 cells
850 cells
1403 cells
1836 cells
3558 cells

500 cells
823 cells
2396 cells
2840 cells
3872 cells

500 cells
640 cells
835 cells
1500 cells
2989 cells

500 cells
723 cells
1244 cells
2247 cells
4371 cells

5.8

8.4

7.1

7.7

5.9

8.7

Hours
24
36
48
60
72
Fold increase
from 24–72 h
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2.4. Dexamethasone-Induced Differentiation Results

Percent protein expression

The ability to differentiate in vitro of the primary mesenchymal stem cell populations isolated
The ability
to differentiate in vitro of the primary mesenchymal stem cell populations isolated was
was verified using a hormonal modulation protocol utilizing dexamethasone, a steroid hormone [16].
verified using a hormonal modulation protocol utilizing dexamethasone, a steroid hormone [16].
The primary cell population of hBM-MSC (BM001) was subjected to a 25-day exposure to
The primary cell population of hBM-MSC (BM001) was subjected to a 25-day exposure to
dexamethasone followed by flow cytometer assay of various cellular markers (ALP, CD105, CD44,
dexamethasone followed by flow cytometer assay of various cellular markers (ALP, CD105, CD44,
CD90, Osteopontin, Osteonectin, Osteocalcein, and RUNX2). A commercially available cell line of
CD90, Osteopontin, Osteonectin, Osteocalcein, and RUNX2). A commercially available cell line of
osteoblasts (HOB, Promocell, cat#C-12720) and unstimulated BM001 patient derived BM cells were
osteoblasts
(HOB,
Promocell,
cat#C-12720)
and primary
unstimulated
BM001cells
patient
derived
BM cells were
used as
controls.
We observed
that the
hBM-MSC
(BM001)
differentiated
into
used as
controls.
We
observed
that
the
primary
hBM-MSC
cells
(BM001)
differentiated
into
osteoblasts following a 25-day treatment with dexamethasone as demonstrated by flowosteoblasts
cytometry
following
a 25-day
with
dexamethasone
as demonstrated
bythe
flow
cytometry
assay. Figure
3
assay.
Figure treatment
3 and Table
3 show
that the markers
displayed by
treated
cells parallel
those of
and Table
3
show
that
the
markers
displayed
by
the
treated
cells
parallel
those
of
known
osteoblast
cells
known osteoblast cells and are significantly changed with regards to their original naïve states.
and are
significantly
changed
with regards
to their original
naïve
withOsteonectin,
dexamethasone
Treatment
with
dexamethasone
increased
expression
of states.
ALP, Treatment
Osteopontin,
and
increased
expression
of ALP,
Osteopontin,
Osteonectin,
and Osteocalcin,
in the BM001
cells
Osteocalcin,
in the
BM001
cells indicating
the activation
of differentiation
toward
theindicating
osteoblast
the activation
lineage. of differentiation toward the osteoblast lineage.

Protein marker
Figure Figure
3. Expression
of differentiation
markers
in hBM-MSC
following
3. Expression
of differentiation
markers
in hBM-MSC
followingdexamethasone
dexamethasone treatment
treatment
as measured
by Flow
The (a)
histogram
is a representative
example
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percentages
of
as measured
by cytometer.
Flow cytometer.
The histogram
is a representative
example
of the
percentages
of expression
various
bone marrow
and osteoblast
differentiation
markers,
and
expression
of variousofbone
marrow
stem cellstem
andcell
osteoblast
differentiation
markers,
beforebefore
and after
after
treatment
with dexamethasone.
Control Osteoblasts
were
used as
positive
control.
Control
treatment
with
dexamethasone.
Control Osteoblasts
were used as
positive
control.
Control
osteoblast
osteoblast
andhBM-MSC
BM001 isolated
hBM-MSC
cells were
antiCD44,
ALP, CD105,
CD44, CD90,
and BM001
isolated
cells were
incubated
withincubated
anti ALP, with
CD105,
CD90, Osteopontin,
Osteopontin,
Osteonectin,
Osteocalcin,
RUNX2 specific
fluoresceinated
flow
Osteonectin,
Osteocalcin,
and RUNX2
specificand
fluoresceinated
antibodies
and flowantibodies
cytometryand
analysis
cytometry
analysis
was
used
to
determine
percent
of
expression
of
the
different
proteins
before
was used to determine percent of expression of the different proteins before and after incubation with
and after to
incubation
with
dexamethasone
to study their differentiation capabilities.
dexamethasone
study their
differentiation
capabilities.
3. comparative
percent differentiation
of expression of the
studied
markers before and
after treatment
with with
FurtherTable
evidence
of osteoblast
was
the morphological
change
associated
dexamethasone.
dexamethasone treatment.

Cell
marker
BM001
(-) Dexa
BM001

ALP

CD105

CD44

65.2%

24.3%

6.9%
54.7

CD90
88.5
%
91.4

Osteopontin

Osteonectin

Osteocal
cin

RUNX2

0.0%

19.2%

20.8%

11.9%
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Table 3. Comparative percent of expression of the studied markers before and after treatment
with
dexamethasone.
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Cell Marker

ALP

CD105 CD44

CD90

Osteopontin

Osteonectin

Osteocalcin

RUNX2

BM001 (−) Dexa
BM001 (+) Dexa
Control Osteoblast

65.2%
100%
93.9%

24.3%
97%
96.8%

88.5%
91.4%
90.1%

0.0%
42.4%
84.7%

19.2%
57.6%
59.6%

20.8%
56.1%
53.3%

11.9%
26.3%
43.9%

6.9%
54.7%
27.9%

Further evidence of osteoblast differentiation was the morphological change associated with
dexamethasone treatment.
Characteristics of the morphological change included the transition from spindle-shaped cells that
Characteristics of the morphological change included the transition from spindle-shaped cells
formed densely populated colonies (Figure 4a) to polygonal cells with less densely packed colonies
that formed densely populated colonies (Figure 4a) to polygonal cells with less densely packed
and colonies
enlargedand
cytoplasmic
space (Figure
4b).
enlarged cytoplasmic
space
(Figure 4b).

(a)

(b)

Figure
4. Phase
contrast
microscopyimages
imagesof
of hBM-MSCs
hBM-MSCs before
dexamethasone
treatment.
Figure
4. Phase
contrast
microscopy
beforeand
andafter
after
dexamethasone
treatment.
(a)
BM002
hBM-MSCs
grown
in
the
absence
of
differentiation
stimuli,
display
spindle-shaped
cellscells
(a) BM002 hBM-MSCs grown in the absence of differentiation stimuli, display spindle-shaped
that
formed
densely
populated
colonies
(100×
magnification);
(b)
BM002
hBM-MSCs
grown
in
that formed densely populated colonies (100× magnification); (b) BM002 hBM-MSCs grownthe
in the
presence
of differentiation
inducing
dexamethasone, display
display polygonal
less
densely
packed
presence
of differentiation
inducing
dexamethasone,
polygonalcells
cellswith
with
less
densely
packed
colonies and enlarged cytoplasmic space (100× magnification).
colonies and enlarged cytoplasmic space (100× magnification).

2.5. 3-Dimensional
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DerivedMesenspheres
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Following
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Following
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characterization
BM002,and
andBM004
BM004
patient
derived
subcultures from each sample were collected and then further cultured in a 96-well aqueous droplet
subcultures from each sample were collected and then further cultured in a 96-well aqueous droplet
culture platform (3-D Hanging Drop Plate, Perfecta). This platform allowed for the sub-culture of
culture platform (3-D Hanging Drop Plate, Perfecta). This platform allowed for the sub-culture
self-assembling spheres of mesenchymal stem cells (mesenspheres). Mesenspheres have been
of self-assembling
spheres of mesenchymal stem cells (mesenspheres). Mesenspheres have been
previously shown to exhibit superior regenerative capacity and are known to produce potent antipreviously
shown
to exhibit
capacity
and are known
producerapid
potent
inflammatory
cytokines
[12]. superior
All three ofregenerative
our patients derived
mesenchymal
cell linesto
displayed
anti-inflammatory
cytokines
[12].
All
three
of
our
patient
derived
mesenchymal
cell
lines
displayed
self 3D-assembly within 24 h.
rapid selfMSC
3D-assembly
within
h. patient sample were seeded at a concentration of 2X10^4 cells per
suspensions
from 24
each
4 cells
MSC suspensions
from
each
patientfor
sample
seeded
at a2. Sphere
concentration
2 × 10was
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drop well and
were
incubated
24 h atwere
37°C and
5% CO
forming of
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◦
assessed drop
in 12 well
replica
wells
forincubated
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studied.
5a demonstrates
a
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and
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forthree
24 hpopulations
at 37 C and
5% COFigure
forming capacity
2 . Sphere
mesensphere
grown
using
the
BM001
primary
cells
imaged
24
h
after
seeding
at
10X
magnification.
was assessed in 12 replica wells for each of the three populations studied. Figure 5a demonstrates a

mesensphere grown using the BM001 primary cells imaged 24 h after seeding at 10× magnification.
Average sphere size after 24 h was very consistent between the replicas across the sample
populations. The diameter of mesenspheres ranged from 212 µm to 253 µm in greatest dimension.
All samples tested displayed excellent self-assembly properties indicative of the viable MSC phenotype.
In addition to culturing mesenspheres in the 3D-Perfecta Hanging Drop Plate, an in-house device
(drop-well) was fabricated that allowed for the culture of much larger mesenspheres. The in-house
device, which is made from a cap of a 1.5 mL microcentrifuge tube glued to a 10 cm tissue culture lid,
enabled the cultured spheroids to reach sizes up to of 4.6 mm. These larger self-aggregated stem-cell
colonies, not only demonstrated similar internal heterogeneity as their smaller counterparts grown
in the Perfecta drop plates, but could theoretically be shaped and re-implanted as is at the site of
(a)
(b)
injury without the need for additional scaffolding material, due to their large size. Figure 5b shows the
Phaseacontrast
microscope
imagesculture.
of hBM-MSCs mesenspheres. (a) Microscope image of a
in-house Figure
device5.with
large active
stem-cell
BM001 hBM-MSCs mesensphere (247µ m largest diameter) grown using the 96-well Perfecta 3D drop

inflammatory cytokines [12]. All three of our patients derived mesenchymal cell lines displayed rapid
self 3D-assembly within 24 h.
MSC suspensions from each patient sample were seeded at a concentration of 2X10^4 cells per
hanging drop well and were incubated for 24 h at 37°C and 5% CO2. Sphere forming capacity was
Int.
J. Mol. Sci.
20, 612 wells for each of the three populations studied. Figure 5a demonstrates a7 of 14
assessed
in 2019,
12 replica
Int.
J. Mol. Sci. 2017,
18, x using the BM001 primary cells imaged 24 h after seeding at 10X magnification.
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mesensphere
grown
plate (100× magnification); (b) Image of a BM001 hBM-MSCs mesensphere (4.6 mm largest diameter)
grown using the in-house drop-well device.

Average sphere size after 24 h was very consistent between the replicas across the sample
populations. The diameter of mesenspheres ranged from 212 µ m to 253 µ m in greatest dimension.
All samples tested displayed excellent self-assembly properties indicative of the viable MSC
phenotype.
In addition to culturing mesenspheres in the 3D-Perfecta Hanging Drop Plate, an in-house
device (drop-well) was fabricated that allowed for the culture of much larger mesenspheres. The inhouse device, which is made from a cap of a 1.5 mL microcentrifuge tube glued to a 10 cm tissue
(a)
(b)
culture lid, enabled the cultured spheroids to reach sizes up to of 4.6 mm. These larger self-aggregated
Figure
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of of
hBM-MSCs
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image
of a of a
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colonies,
onlymicroscope
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internalmesenspheres.
heterogeneity
smaller
counterparts
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(a)their
Microscope
image
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(247µ
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largest
diameter)
grown
using
the
96-well
Perfecta
3D
drop
BM001
hBM-MSCs
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Each of the scaffolds tested in this study was inoculated with a one milliliter suspension
consisting of 5X10^4 viable patient derived MSCs. The scaffold was inoculated by directly pipetting
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of the scaffold and the cells do not display prominent apoptotic regions.; (b) Representative
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allow for significant hBM-MSC integration. The MSCs adhered to the outer surfaces of the scaffold
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on a 60/40 hydroxyapatite scaffold, and stained with Haematoxylin and Eosin (100× magnification).
The viable hBM-MSC population can be seen in significant numbers throughout a full thickness section
of the scaffold and the cells do not display prominent apoptotic regions.; (b) Representative microscope
image of a cross-section of hBM-MSCs seeded and cultured on a PLGA scaffold with 200 µm pores,
stained with Haematoxylin and Eosin (100× magnification). The PLGA scaffold did not allow for
Int. J. Mol.
Sci. 2017,hBM-MSC
18, x
10 of 16
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The protocol we developed cultures MSCs in vitro within a 3-week window. We combined two
methodologies: A traditional, two-dimensional substrate-based adherent monolayer method and a
three-dimensional spheroid culture method. Notably, the 3D spheroid culture allowed production of
hBM mesenchymal cells that retained better osteoblast differentiation capacity over a monolayer
culture of hBM-MSCs without the need to use chemical or hormonal modulation.
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methodologies: A traditional, two-dimensional substrate-based adherent monolayer method and a
three-dimensional spheroid culture method. Notably, the 3D spheroid culture allowed production
of hBM mesenchymal cells that retained better osteoblast differentiation capacity over a monolayer
culture of hBM-MSCs without the need to use chemical or hormonal modulation.
More importantly, we have demonstrated in this study that the MSCs that were harvested and
expanded from trauma donors following a surgical repair of a long bone fracture, maintained their
stem-like phenotype, which is necessary for effective wound healing use and is readily adaptable
to simple percutaneous harvesting techniques such as iliac crest or trochanteric percutaneous
needle aspiration.
Our protocol is uniquely tailored to clinical use due to the utilization of patient derived growth
factors present in patient-derived serum (PDS), again obtained with the needle aspirations or serum,
instead of animal-derived serum such as fetal bovine serum. In regenerative medicine the use of
stem-cell therapies can offer very favorable results, however, in many cases these therapies also pose
some major risks. Although fetal bovine serum (FBS) is effective, relatively inexpensive, and easily
accessible, its use in cell-based therapies intended for implantation into humans is not an acceptable
practice. This is due to the increased risk of pathogen transfer that its use entails. The results of the 3D
expansion show the readiness of the newly differentiated osteoblasts to generate new bone and thus
potentially initiate the remodeling mechanisms critical for bone healing. We believe that this alone
may represent an advancement in atrophic non-union treatment via similar bone grafting harvesting
and insertion through percutaneous techniques.
We envision that the integration of this technology in a clinical setting would be a staged process.
By developing this method, it is our goal to have patients fulfilling the appropriate criteria present
to a referral center to undergo minimally invasive stem cell harvest and expansion ahead of their
surgery, and subsequent implantation treatment. Eventually, a referral could be offered for the stem
cell expansion only and the surgical implantation procedures could be performed at the referring
institution. One even can envision generating custom shaped scaffolds for large bony defects resulting
from trauma or tumor resection, possibly even 3D printed, and seeding them with autogenous
generated ostoblast stem cells for improved and faster incorporation taking established methods,
such as the Masquelet Technique (a 4–12-week process), to the next level [17].
The timing with which we are able to generate autogenous osteoblasts is on par, if not faster
than, this membrane based defect auto-grafting methodology commonly employed for bony defects,
and potentially could exceed the size restrictions currently limiting this technique.
Future research in this field utilizing the same or similar platforms could yield complimentary
regenerative techniques for cartilage, muscle, tendon, skin, and other individual ex-vivo fabrication
of autologous patient tissues suitable to repair maxillofacial and orthopedic defects. More studies
will be needed to advance this dual culture method based on a traditional, two-dimensional adherent
monolayer method and a three-dimensional spheroid culture method to translate it to the clinics.
4. Materials and Methods
4.1. Study Design and Surgical Procedure for Harvesting hBM-MSCs
Our goal was to standardize the collection and expansion of human bone marrow (hBM) stem
cells harvested from patients undergoing intramedullary nail fixation for closed femoral fractures at
Marshall University. Patients were selected based on their injuries and suitability for signature of an
informed consent in the perioperative setting and enrollment in an IRB protocol at Marshall University
(IRB protocol# 393960). The study was conducted in accordance with the ethical principles provided
by the Declaration of Helsinki and the principles of good clinical practice.
The hBM samples were collected using a reamer irrigator aspirator (RIA) and filtration system for
sample collection and concentration or a standard reaming technique from the fractured femur during
the process of preparation of the canal for intramedullary implants. Aspirated material and collected
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bony fragments from the reaming were transported to the lab within three hours, after which the
material was immediately disassociated and plated into a 15cm tissue culture petri dish in RPMI-1640
and incubated at 37 ◦ C in the presence of 5% CO2 .
4.2. Patient Samples
BM001, BM002, and BM004 samples were collected as a bone marrow aspirate from an 11-year-old
male, a 25-years old male and a 30-years old female, respectively. Samples were transferred from
surgery directly to the tissue culture lab and maintained at room temperature (transfer time was less
than 3 h), ensuring optimal sample viability. BM003 was collected as a bone marrow aspirate from a
30-year-old female, but was excluded from the study due to non-viability of the sample.
4.3. Patient-Derived Serum Preparation (PDS)
Excess whole blood collected from the surgical site was centrifuged to separate out the various
blood components. Blood serum was removed from the platelet layer and filtered through a 0.45 µm
membrane. The platelet layer was then lysed with red cell lysis buffer, a hypotonic saline solution,
and the resulting suspension was processed through a 0.45 µm membrane. The processed suspension
was added back to the whole patient serum. 500 µL aliquots were then frozen and stored at −20 ◦ C
until further use. This autologous serum, herein referred to as PDS was added to the basal stem-cell
culture media.
4.4. Cell Lines and Growth Medium
Osteoblasts (HOB) (PromoCell, catalogue C-12720) were grown in Osteoblast Basal Medium
(PromoCell, #C27001). hBM-MSC were plated in RPMI-1640 and later on grown in DMEM-high
glucose with Pyruvate (Thermo Fisher Scientific) supplemented with 10% patient-derived serum (PDS)
and 2% penicillin/streptomycin solution.
4.5. hBM-MSCs Culture and Colony Expansion
After a period of 48 h, the MSCs were transitioned from RPMI-1640 to DMEM media. Cells were
then expanded from their original colonies to form confluent monolayers on several 15 cm polystyrene
tissue culture treated petri dishes. Accutase® (ThermoFisher Scientifics), was used to sub-culture
the hBM-MSCs. In this growth period of approximately two weeks, the cells were monitored
on a daily basis for morphological changes and media were replaced twice a week on average.
During this phase representative samples were assessed for cell surface markers to further assess if
mesenchymal stem cells had been isolated. The hBM-MSCs were then plated in Perfecta 3D Hanging
Drop Plates® . Cells were seeded in 50 µL drops of DMEM high-glucose medium with L-glutamine
and sodium pyruvate and allowed to self-assemble for 24 h prior to viewing. After 24 h the assembled
mesenchymal spheres (mesenspheres) were photographed. Mesenspheres were cultured in suspension
for 7 days with daily media changes and monitored for circumferential growth. After the 7-day period
representative spheres were harvested and analyzed for extracellular matrix (ECM) production and
calcium deposition, as well as internal core viability.
4.6. Cell Counting
Cells were dissociated using Accutase® (ThermoFisher Scientific) and counted using Trypan blue
exclusion method and a Cellometer-Mini Automatic Cell Counter (Nexcelom).
4.7. Flow Cytometry Characterization
Cells to be assayed were dissociated using Accutase® (Thermo Fisher Scientific). Incubation with
FCR blocking reagent (Miltenyi Biotech) for 15 min was used to limit unspecific antibody binding.
Samples were incubated with fluorescence labeled specific antibodies or nothing as negative controls
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for 30 min at 4oC. Following incubation, cells were washed with flow cytometer buffer and centrifuged
to remove the unbound antibodies. Cells were then resuspended in flow cytometer buffer and analyzed
through an Accuri C6 Flow Cytometer (BD Biosciences).
4.8. Scaffold Preparation and Inoculation with Expanded hBM-MSCs
Various scaffold materials were analyzed for cell integration of hBM-MSCs. Biomaterials routinely
used in bone grafting were either purchased or fabricated in house. The use of scaffolding in this
study is driven from the clinical desire to fill large defects with an autogenous type bone graft, where
typical graft harvesting, such as iliac crest bone graft (ICBG), fails to yield adequate amounts of
material for larger voids and thus must be augmented with so-called “bone void fillers”. Furthermore,
ICBG harvesting is generally considered to be a very unpleasant, painful and even invasive procedure
for the patient. Thus we employed various commonly used and potentially useful candidate materials
for study and control purposes while allowing for the development of a percutaneous method of
harvesting such as needle aspiration from the iliac wing or even the greater trochanter of the hip [18].
We used a biphasic calcium phosphate bone substitute material with a 60/40 Hydroxiapatite
(HA)/Tricalcium Phosphate (TCP) ratio blend biomatrix (kindly donated from Caroline J. Wilcock,
School of Clinical Dentistry, University of Sheffield, UK), which is taken to represent the commonly
used ceramic based HA bone void fillers in orthopaedic non-unions and defects; Acellular bone
composite disc molded from bone fragments collected in reaming at sample collection to represent
bone autograft material; Cancellous bone cubes (Allowash® ) allografts (Life Link Tissue Bank, Tampa,
FL); PLGA (poly lactic-co-glycolic acid) constructs with 200 µm pore size (Bioengineering Department,
University of Naples “Federico II”, Italy); and Woven chitin derived fiber constructs (kindly donated
by Inoue Kuzo, FUENCE Limited, Japan).
The 60/40 Hydroxyapatite biomatrix was chemically hydrated for 3 min using 70% ethanol
prior to a saline rinse. Patient derived hBM-MSCs were seeded into the 60/40 hydroxyapatite
scaffold and cultured at 37 ◦ C and 5% CO2 in untreated tissue culture Petri dishes using RPMI-1640,
and 10% PDS, 2% Penicillin/Streptomycin. The medium was changed every 3 days for 15 days.
The inoculated scaffolds were then processed and stained for microscopic analysis of integration,
expansion, and differentiation.
Acellular bone autograft composites were molded and sterilized using hot ethanol. The resulting
disks weighing approximately 300 mg were then freeze-dried prior to seeding with hBM-MSCs.
Allowash ® cancellous bone cubes with an average mass of 230mg were rinsed and hydrated with
saline. PLGA derived constructs of varying pore sizes were rinsed in saline prior to seeding with
patient derived hBM-MSCs. Woven chitin derived fibers were sterilized in an autoclave prior to
hydration with saline. Patient derived hBM-MSCs were seeded into the scaffolds and cultured at
37 ◦ C and 5% CO2 in untreated tissue culture Petri dishes using high-glucose DMEM, and 10% PDS,
2% Penicillin/Streptomycin. The medium was changed every 3 days for 15 days. The inoculated disk
was then processed and stained for microscopic analysis of integration, expansion, and differentiation.
Analysis of the woven fibers scaffold was limited to cell integration.
4.9. Hormonal Induction of hBM-MSC Osteogenic Differentiation to Confirm Differentiation Potential
Powder-form dexamethasone (Sigma) was dissolved in DMSO and added to the hBM-MSC culture
medium at a final concentration of 100 nm (as per the specification of Tenenbaum and Heersche) for
25 days. The medium was changed every other day. At the end of the 25th day, morphology was
assessed and recorded in all samples. The cells were analyzed for cell surface and intracellular
osteoblast markers to confirm the presence of differentiated osteoblasts.
4.10. Staining Protocols to Study Cell-Seeding Efficacy, Cellular Integration, Vitality, and Differentiation
Methyl Thyazolyl Tretrazolium salt staining. To determine cell-seeding efficacy on scaffolds we
used a methyl tetrazolium salt (MTS) assay (MP Biomedical Fisher Scientific). The cell-seeded scaffolds
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and controls (cells seeded on culture plates) (n = 3 for all groups) were thoroughly rinsed in PBS and
then incubated in 0.5 mg MTS solution in DMEM high glucose supplemented with 10% PDS. Allowash
bone cubes and patient derived composite bone disks that were seeded with the MSC cell populations
along with their corresponding negative controls were incubated in 10mL MTS solution at 37 ◦ C in a
CO2 incubator for 5 h. Bone disks and Allowash cubes were then compared to their unseeded negative
controls and images were taken for qualitative data analysis.
Haematoxylin and Eosin staining. To study cellular integration within the various scaffolds,
specimens were fixed using a 10% neutral buffered formaldehyde fixative (ThermoFisher) solution
for 10 h. Samples were then embedded in paraffin and cut with a microtome (Sakura tissue Tec) at
20 µm sections and mounted onto microscope slides. Slides were processed through an automated
Haematoxylin and Eosin staining procedure and mounted with a coverslip for viewing and imaging.
Trypan Blue Staining. To study cellular vitality, 1mL of trypan blue solution (Sigma Aldrich) was
used to stain the mesenspheres for 10 min before imaging.
Alizarin Red Staining. To study osteoblast differentiation of the bone marrow cells, mesenspheres
were “squash-prepped” onto microscope slides, dehydrated with 95% ethanol, followed by 100%
acetone for 2 min each. The slides were dipped in 1 g/50 mL Alizarin red (Sigma Aldrich) solution in
water for 3 min. Excess die was flicked off. The slides were dipped in 100% acetone for 30 s followed by
30 s of xylene. Coverslips were mounted to the slides for viewing and imaging. Cellular differentiation
was imaged by light microscopy and cells containing mineral deposits were identified by bright red by
Alizarin Red staining.
4.11. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6 statistical software (Graphpad, Inc., La
Jolla, CA, USA). One and two-way analysis of variance (ANOVA) with Tukey or Bonferroni multiple
comparisons post-test was used to determine the statistical significance of the differences between
experimental groups. p-values of less than 0.05 were considered statistically significant.
5. Conclusions
The bone marrow mesenchymal stem cell isolation and culture protocol we have developed will
have a positive impact in the field of head tissue and orthopedic regenerative medicine considering its
clinical applications in scenarios where conditions of significant bony defects and fracture non-unions
occur. A streamlined clinical protocol of autologous host tissue acquisition to regenerate missing bony
structure to alleviate pathologic conditions represents a substantial medical advance in several clinical
scenarios, including traumatic bone loss, surgical excision of areas of infected bone, or tumor resections.
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